Why the study?
The precise identities of distinct immune cell subsets and their molecular mediators governing pathological progression in viral myocarditis remain significant knowledge gaps.
Integrated single-cell and bulk RNA analysis identifies T cells as key immune players and CCL3 as a potential novel biomarker for viral myocarditis.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for CCL3 and T-cell roles in viral myocarditis; human studies required before biomarker or therapeutic consideration.
Viral myocarditis (VMC), a multifaceted pathological condition predominantly triggered by viral infections, has emerged as a major worldwide healthcare concern due to its intricate pathogenesis and substantial disease burden. Although the centrality of immune dysregulation in driving VMC progression is well-established, the precise identities of distinct immune cell subsets and their molecular mediators governing pathological progression continue to present significant knowledge gaps. Single-cell datasets were integrated using quality control, batch correction, and normalization. The FindAllMarkers function identified marker genes for each cluster. Cell types were annotated based on literature-derived marker genes. DESeq2 was employed to identify differentially expressed genes in T cells. CellChat was used to explore intercellular communication and identify key ligand-receptor signaling pathways. Receiver operating characteristic curves assessed the predictive performance of key factors in a validation cohort. T cells were re-annotated for higher-resolution subtyping, and pseudotime analysis depicted the cell trajectories of T cell subtypes. Integrated single-cell data revealed a comprehensive single-cell atlas of VMC. Mechanistic delineation of T cell as principal pathogenic effectors emerged through multi-omics interrogation incorporating single-cell transcriptomic profiling and pathological trajectory reconstruction; functional genomics analyses further substantiated their cardinal involvement in cardiotropic viral pathogenesis. Additionally, communication analysis highlighted CCL as a critical immune regulatory pathway for T cell interactions in VMC. Significant upregulation of CCL3 was confirmed in the validation cohort, establishing it as a potential biomarker and therapeutic target for VMC. Pseudotime analysis and re-annotation of T cell subpopulations revealed significant enrichment of T.8EFF.OT1LISO and T.Tregs in VMC. This study identifies T cells as key immune players in VMC, with CCL3 proposed as a novel biomarker for the condition.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: